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Secondary myelodysplastic syndrome and acute myelogenous leukemia (sMDS/sAML) are the most serious
secondary events occurring after immunosuppressive therapy in patients with aplastic anemia. Here we
evaluate the outcome of hematopoietic stem cell transplantation (HSCT) in 17 children and young adults with
sMDS/sAML after childhood aplastic anemia. The median interval between the diagnosis of aplastic anemia
and the development of sMDS/sAML was 2.9 years (range, 1.2 to 13.0 years). At a median age of 13.1 years
(range, 4.4 to 26.7 years), patients underwent HSCT with bone marrow (n ¼ 6) or peripheral blood stem cell
(n ¼ 11) grafts from HLA-matched sibling donors (n ¼ 2), mismatched family donors (n ¼ 2), or unrelated
donors (n ¼ 13). Monosomy 7 was detected in 13 patients. The preparative regimen consisted of busulfan,
cyclophosphamide, and melphalan in 11 patients and other agents in 6 patients. All patients achieved
neutrophil engraftment. The cumulative incidence of grade II-IV acute graft-versus-host disease (GVHD) was
47%, and that of chronic GVHD was 70%. Relapse occurred in 1 patient. The major cause of death was
transplant-related complication (n ¼ 9). Overall survival and event-free survival at 5 years after HSCT were
both 41%. In summary, this study indicates that HSCT is a curative therapy for some patients with sMDS/sAML
after aplastic anemia. Future efforts should focus on reducing transplantation-related mortality.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) from a
HLA-matched sibling donor is the currently recommended
ﬁrst-line treatment in young patients with aplastic anemia
[1], associated with an overall survival (OS) rate of >90%
in children [2,3]. This approach is limited by the unavail-
ability of such donors for the majority of patients, however.
For patients without a matched sibling donor, immune-
suppressive therapy (IST) comprising antithymocyte glob-
ulin (ATG) and cyclosporine A (CSA) has been the standard
therapy, restoring hematopoiesis in approximately two-
thirds of patients [2-6]. Currently, long-term survival after
IST is approximately 80% to 90% in children [2,3,7,8]. Never-
theless, IST remains a suboptimal option; blood counts often
remain subnormal, and approximately one-third of treat-
ment responders experience relapse at a later time point.dgments on page 429.
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13.11.031Moreover, a small number of patients develop serious com-
plications, such as secondary myelodysplastic syndrome/
acute myelogenous leukemia (sMDS/sAML) or paroxysmal
nocturnal hemoglobinuria [5,6,8].
Previous studies have shown that sMDS/sAML develops in
2% to 26% of patients with aplastic anemia after IST and is
associated with a very poor prognosis [5,8-15]. HSCT is
currently the only curative approach for such patients, but to
our knowledge, efﬁcacy has not yet been systematically
evaluated. Here we report on the outcomes of HSCT in 17




This retrospective study included 17 German children and young adults
(13 males and 4 females) who had undergone HSCT for sMDS/sAML after
IST for aplastic anemia in childhood. Among 287 children (age<18 years) who
underwent IST in the German Speaking Society of Pediatric Oncology and
Hematology (GPOH) SAA-94 study (November 1993 to September 2011) [3],14
developed sMDS/sAML. In the European Working Group of Myelodysplastic
Syndrome in Childhood (EWOG-MDS) studies (EWOG-MDS 98, January 1997
to December 2006; EWOG-MDS 2006, January 2007 to September 2011;
ClinicalTrial.gov identiﬁer: NCT00662090), an additional 5 German children
with sMDS/sAML after aplastic anemiawere identiﬁed. Of these 19 patients,17
had undergone HSCT and were included in this study. Study approvals were
obtained from the Institutional Review Boards of each participating institu-
tion. Written informed consent was provided by each patient’s parents in

























1 8.6 M Idiopathic ATG/CSA 3 PR 3.0 Monosomy 7 AML Disseminated
candidiasis
2 14.5 M Idiopathic ATG/CSA 15 NR 1.5 Monosomy 7 RA
3 8.9 F Idiopathic ATG/CSA 24 PR 2.2 Monosomy 7 RAEB
4 8.4 F Idiopathic ATG/CSA 30 NR 2.6 Monosomy 7 AML Sepsis
5 9.8 M Idiopathic ATG/CSA 0 PR, relapse 2.3 Monosomy 7 RA
6 3.2 M Hepatitis* ATG/CSA 26 NR 3.3 Monosomy 7 AML Invasive
aspergillosis
7 6.7 M Idiopathic ATG/CSA 8 PR 2.6 Monosomy 7 RA
8 13.0 F Idiopathic ATG/CSA 5 PR 2.9 Monosomy 7 RA
9 11.1 M Idiopathic ATG/CSA 1 PR 4.0 Monosomy 7 RA
10 10.1 M Idiopathic ATG/CSA 4 PR, relapse 11.1 Monosomy 7 RAEB
11 3.9 F Idiopathic ATG/CSA 24 NR 1.6 Monosomy 7y RA
12 2.8 M Idiopathic ATG/CSA 1 NR 1.2 Monosomy 7 RAEB Gastrointestinal
bleeding
13 14.5 M Idiopathic ATG/CSA 3 CR, relapse 10.9 Monosomy 7 CMML (17%
BM blasts)
14 12.6 M Idiopathic CSA 19 CR 6.2 del (7)(q22) AML PNH
15 13.2 M Idiopathic ATG 0 PR 13.0 Normal CMML (13%
BM blasts)
16 8.8 M Hepatitis ATG/CSA 12 CR 4.2 Normal RAEB
17 12.5 M Idiopathic ATG/CSA 6 PR 8.6 Normal AML Multiple abscess,
pulmonary
aspergillosis
AA indicates aplastic anemia; G-CSF, granulocyte colony-stimulating factor; CR, complete response; PR, partial response; NR, nonresponse; AML, acute mye-
logenous leukemia; RA, refractory anemia; CMML, chronic myelomonocytic leukemia; RAEB, RA with excess blasts; PNH, paroxysmal nocturnal hemoglobinuria.
* This patient underwent liver transplantation.
y This patient had constitutional mosaic trisomy 21. Monosomy 7 was detected only in the subpopulation of hematopoietic cells with trisomy 21.
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Aplastic anemia was diagnosed as pancytopenia, hypoplastic bone
marrow (BM) without dysplasia, as described previously [3]. The diagnosis
was conﬁrmed by a central review of the BM biopsy specimens by reference
pathologists in 13 patients. The karyotype was normal in 10 patients, and
metaphase analysis data were not available for 7 patients. In the latter pa-
tients, negative results of ﬂuorescent in situ hybridization for monosomy 7
and trisomy 8were available for 5 patients. The median age at diagnosis was
8.9 years (range, 2.8 to 14.5 years) (Table 1). Fanconi anemia and other
inherited BM failure syndromes had been excluded in all patients. One pa-
tient had a constitutional trisomy 21 mosaic with no clinical signs of Down
syndrome (patient 11).
Fifteen patients received an IST regimen with horse ATG (15 mg/kg/
day  8 days; Lymphoglobulin; Genzyme, Cambridge, MA) and CSA
described by the GPOH-SAA-94 study as reported previously (Table 1) [3].
Two patients diagnosed with aplastic anemia before 1994 received horse
ATG (n ¼ 1) or CSA (n ¼ 1) only. Complete and partial response to IST was
evaluated as reported previously [3]. Nonresponsewas consideredwhen the
criteria for partial responsewere not fulﬁlled. Relapse of aplastic anemiawas
deﬁned by conversion to nonresponse from partial or complete response.
Diagnosis of Secondary MDS/AML
Herein, sMDS/sAML after IST was diagnosed if 1 of the following criteria
was met: (1) 5% blasts in BM, (2) evolution of an abnormal karyotype and
myelodysplasia, or (3) hypercellular BM in the presence of pancytopenia and
myelodysplasia. Morphology was subdivided using the French-American-
British (FAB) classiﬁcation [16]. The highest FAB classiﬁcation before HSCT
for each patient is shown in Table 1. Monosomy 7 was the most common
cytogenetic aberration. The median interval between the diagnosis of
aplastic anemia and the development of sMDS/sAML was 2.9 years (range,
1.2 to 13.0 years).
Pre-HSCT Condition and Treatment
Thirteen patients were receiving CSA therapy when they were diag-
nosed with sMDS/sAML. Three patients developed invasive fungal in-
fections, and 3 patients had severe bacterial infections before undergoing
HSCT (Table 1). Pre-HSCT therapy was performed at the discretion of the
treating physician. Patient 1 achieved remission from sAML after 1 course of
chemotherapy, but developed disseminated candidiasis. Patient 17, with
sAML, did not achieve remission after 2 courses of chemotherapy and
developed multiple abscesses and fungal pneumonia. Patient 13, with themorphology of chronic myelomonocytic leukemia and 17% blasts in BM,
received 7 courses of azacytidine therapy, which resulted in the reduction of
blasts in the BM (<5%) and improvement of blood counts before HSCT.
Transplantation Procedure
Transplantation procedures, including stem cell sources, donors, pre-
parative regimens, and graft-versus-host disease (GVHD) prophylaxis are
summarized in Table 2. Donors and recipients were tested for HLA
compatibility by serologic typing to identify HLA-A, -B, and -C (class I) and by
high-resolutionmolecular typing to detect HLA-DRB1 (class II) speciﬁcities in
12 patients and by high-resolution molecular typing for both class I and II in
5 patients. Three patientswho received a transplant from an unrelated donor
had an HLA mismatch: patient 3 (HLA-B) and patients 9 and 13 (HLA-C).
Eleven patients received a preparative regimen consisting of busulfan
(oral 16 mg/kg/day for 4 days in 9 patients, i.v. in 2 patients), cyclophospha-
mide (60 mg/kg/day for 2 days), and melphalan (140 mg/m2 in a single dose),
a schedule recommended by the EWOG-MDS study for patients with high-
risk MDS (Table 2) [17]. Two patients were given a regimen with thiotepa
(8 mg/kg/day for 1 day), treosulfan (14 g/m2/day for 3 days), and ﬂudarabine
(40 mg/m2/day for 4 days), as currently recommend by the EWOG-MDS for
patients age 12 years with high-risk MDS to reduce transplantation-related
toxicity in older children. The remaining 4 patients received conditioning
regimens according to each medical center policy (Table 2).
Themedian dose of infused nucleated cells was 2.4108 (1.5-4.0 108)/
kg of recipient body weight for BM (n ¼ 6). The median dose of infused
CD34þ cells for peripheral blood stem cells was 5.4  106/kg (range,
2.1-10.3  106/kg) of recipient body weight in 9 patients; this information
was not available for 2 patients.
Deﬁnitions and Statistics
Acute and chronic GVHD were diagnosed and graded according to
previously reported criteria [18-20]. Neutrophil engraftment was deﬁned as
the ﬁrst of 3 consecutive days with a neutrophil count >0.5  109/L, and
platelet engraftment was deﬁned as the ﬁrst of 3 consecutive days with an
unsupported platelet count >20  109/L. The Kaplan-Meier method was
used to estimate survival rates, and a 2-sided log-rank test was used to test
the equality of survivorship functions in different subgroups [21]. Death,
relapse, and graft failure were classiﬁed as qualifying events for event-free
survival (EFS). Statistical analysis of data was performed using SPSS for
Windows version 20.0 (IBM, Armonk, NY) and NCSS 2004 (Number
Cruncher Statistical Systems, Kaysville, UT).
Table 2
Transplantation Procedures and Outcomes
ID Age at HSCT, yr Interval from MDS/AML to HSCT, mo Pre-HSCT Therapy Donor Stem cell Preparative regimen GVHD prophylaxis GVHD FU, d Outcome
Acute Chronic
1 12.1 7 1  AML-Tx, CR Sibling BM Bu/Cy/Mel CSA I No 5098 alive (KS:100%)
2 16.3 3 None MMFD PB Bu/Cy/Mel/ATG CSA/MTX I Extensive 5017 TRM (chronic GVHD)
3 11.7 7 None UD PB Bu/Cy/Mel CSA/MTX 0 Limited 4293 alive (KS:100%)
4 11.2 2 None UD PB Bu/Cy/Thio/ATG CSA/MTX 0 d 48 relapse and died after 2.HSCT
5 12.2 2 None UD PB Bu/Cy/Mel/ATG CSA IV d 52 TRM (acute GVHD, sepsis)
6 6.7 2 None UD PB Bu/Cy/Mel/ATG CSA/MTX IV d 38 TRM (acute GVHD, sepsis)
7 9.8 6 None UD BM Bu/Cy/Mel/ATG CSA/MTX III Limited 2589 alive (KS:100%)
8 16.4 6 None UD BM Treo/Thio/Flu/ATG CSA/MTX III Extensive 1521 alive (KS:100%)
9 15.6 6 None UD PB Bu/Cy/Mel/ATG CSA/MTX III Extensive 671 TRM (chronic GVHD)
10 21.5 4 None UD PB FLAMSA-Thio/Cy/Mel/ATG FK506/MTX 0 Extensive 368 TRM (TAM)
11 6.7 14 None UD BM Thio/Cy/TBI (12Gy)/ATG CSA/MTX II Limited 300 TRM (pulmonary embolism)
12 4.4 10 None UD PB Bu/Cy/Mel/ATG CSA/MTX IV d 41 TRM (acute GVHD)
13 26.2 11 7  azacitidine UD PB Treo/Thio/Flu/ATG CSA/MTX I No 829 alive (KS:70%)
14 19.1 3 None UD PB Bu/Cy/Mel/ATG CSA/MTX/MMF II No 1974 alive (KS:100%)
15 26.7 6 None UD BM Bu/Cy/Mel/ATG CSA 0 d 29 TRM (sepsis, cerebral infarction)
16 13.1 1 None Sibling PB Bu/Cy/Mel CSA/MTX 0 d 46 TRM (ARDS)
17 21.4 3 2  AML-Tx, no CR MMFD BM FLAMSA-CY/TBI (4 Gy)/ATG CSA/MTX 0 d 98 TRM (intracranial hemorrhage)
AML-Tx indicates AML chemotherapy; MMFD, mismatched family donor; UD, unrelated donor; PB, peripheral blood; Bu, busulfan; Cy, cyclophosphamide; Mel, melphelan; Thio, thiotepa; Flu, ﬂudarabine; FLAMSA, ﬂudarabine,
cytarabine, and amsacrine; TBI, total body irradiation; MTX, methotrexate; FK506, tacrorims; MMF, mycophenolate mofetil; FU, follow-up after HSCT; KS, Karnofsky score; ARDS, acute respiratory distress syndrome; TAM,
transplantation-associated microangiopathy.
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Engraftment and GVHD
Sustained neutrophil engraftment was achieved in all
patients at a median of 15 days (range, 9 to 30 days) after
HSCT. For patients achieving platelet engraftment (n¼ 13/17),
the median time to obtain platelet recovery was 29 days
(range, 5 to 61 days). The cumulative incidence of grade II-IV
acute GVHD was 47% (95% conﬁdence interval [CI], 28% to
78%), whereas that of grade III-IV acute GVHD was 35% (95%
CI, 19% to 67%). The cumulative incidence of chronic GVHD
was 70% (95% CI, 47% to 100%).
Relapse and Complications
Relapse of sAML was observed on day 26 after HSCT in
1 patient (patient 4). This patient underwent a second
HSCT from a haploidentical father at 36 days after the ﬁrst
HSCT, but died of fungal infection on day 11 after the second
HSCT.
Severe infections were commonly observed after HSCT,
including sepsis (n ¼ 6), pneumonia (n ¼ 3), invasive
aspergillosis (n ¼ 4) and Epstein-Barr viruseassociated
lymphoproliferative disorder (n ¼ 1). Other severe compli-
cations included hepatic veno-occlusive disease (n ¼ 2),
transplantation-associated microanigiopathy (n ¼ 1), cere-
bral infarction (n ¼ 1), intracranial hemorrhage (n ¼ 1),
acute renal failure (n ¼ 1, requiring dialysis), chronic renal
insufﬁciency with Fanconi syndrome (n ¼ 1), and multiple
osteonecrosis (n ¼ 1).
Survival and Transplantation-Related Mortality
Six patients were alive and disease-free after HSCT, and 11
patients died of relapse (n ¼ 1) or transplantation-related
complications (n ¼ 10). Major causes of transplantation-
related mortality (TRM) were infections and GVHD
(Table 2). OS and EFS at 5 years were 41% each (95% CI, 18%-
64%), with no difference between patients with refractory
anemia and advanced diseases (44% versus 38%; P ¼ not
signiﬁcant). The median duration of observation was
7.1 years for survivors (Table 2). Karnofsky score at the time
of the last follow-up was 100% in 5 patients and 70% in 1
patient, who had multiple osteonecroses, chronic pain syn-
drome, and chronic renal insufﬁciency.
No association with survival was seen in factors such as
age at HSCT, interval between diagnosis of aplastic anemia
and diagnosis of sMDS/sAML, interval between diagnosis of
sMDS/sAML and HSCT, stem cell source (peripheral blood
versus BM), and conditioning regimen (busulfan/cyclophos-
phamide/melphalan versus others).
DISCUSSION
Clonal evolution is one of the most serious secondary
events in patients with aplastic anemia who were treated
with IST. In particular, patients who develop monosomy 7 or
an elevated blast count have a very poor prognosis
[9,11,15,22-24]. Although HSCT is currently the only curative
approach for these patients, data on HSCT are very limited in
both children and adults. Although a few patients who
developed sMDS/sAML and underwent HSCT were described
in previous reports on IST in aplastic anemia [2,8,11,25],
detailed information is not provided.
Here we report outcomes of 17 children and young adults
with sMDS/sAML after IST for aplastic anemia. To the best of
our knowledge, this is the ﬁrst report to focus on outcomes of
HSCT in sMDS/sAML after aplastic anemia. Limitations of this
study include the small number of patients, thewide range ofyears in which HSCT was performed, the varied conditioning
regimens, and the retrospective study design. Nevertheless,
this study demonstrates that HSCT is feasible and can be a
curative therapy in this situation, resulting in a 5-year EFS
rate of 41%. Neutrophil engraftment was observed in all pa-
tients, and the relapse rate was low.
The major problem was the high incidence of severe in-
fections and acute GVHD, resulting in the high rate of TRM
considering the young age of the patients. The high incidence
of severe infections is clearly related to the duration and
intention of the immune-compromised status before HSCT
induced by CSA therapy and prolonged neutropenia owing to
the underlying disease. Indeed, 3 of our patients had an
invasive fungal infections and 2 patients had a severe bac-
terial infection before undergoing HSCT. The high incidence
of acute GVHD in our cohort may be explained by toxic
conditioning regimens and a low-resolution HLA typing in
the majority of patients.
OS and EFS in this study were similar to the results of
major previous reports on HSCT in MDS in children, resulting
in an EFS rate of 38% to 59% [17,26-29], although a comparing
results among studies is difﬁcult, owing to the heterogeneity
of MDS subtypes and donors in studies. Compared with the
outcomes of HSCT in patients with sMDS/sAML after
chemotherapy and/or radiotherapy with a 15% to 24% EFS
rate, the results of sMDS/sAML after aplastic anemia appear
to be favorable [30,31]. However, in contrast to the 90% OS in
recent reports on HSCT from an unrelated donor in patients
with aplastic anemia [32,33], the OS of 40% in the present
study is unsatisfactory. Because children with aplastic ane-
mia who do not respond to the ﬁrst course of IST may not
respond to an additional course [34], and because nonre-
sponse to IST and long-term granulocyte colony-stimulating
factor administration (10 to 12months) have been reported
as risk factors for the development of sMDS/sAML
[4,13,14,24], patients with no response or relapse after IST
should undergo unrelated donor-HSCT without delay.
Given that TRM was the major problem identiﬁed in this
study, less-toxic preparative regimens should be introduced
in patients who develop sMDS/sAML after aplastic anemia.
The recent EWOG-MDS analysis of 97 patients with primary
advanced MDS who underwent HSCT with a busulfan/
melphalan conditioning regimen found a 5-year EFS of 59%
[17], along with a high TRM rate in children age 12 years.
Thus, the current EWOG-MDS group introduced a treosulfan/
ﬂudarabine/thiotepa regimen for older children (age
12 years) with advanced MDS as well as sMDS/sAML in an
effort to reduce TRM. The regimen is apparently associated
with reduced HSCT toxicity while retaining myeloablative
and antimalignancy effects [35-38]. Two patients in this
cohort received a treosulfan/ﬂudarabine/thiotepa regimen;
both were still alive at the time of this report. Further studies
with larger numbers of patients are needed to evaluate the
efﬁcacy of this regimen.
In summary, this study demonstrates that HSCT is feasible
and potentially curative in patients with sMDS/sAML after
aplastic anemia. Future studies need to focus on reducing
TRM to potentially increase the cure rate in these children.
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